Cancer Research and Treatment

Original Articles

Identification of EGFR Mutations by Immunohistochemistry with EGFR Mutation–Specific Antibodies in Biopsy and Resection Specimens from Pulmonary Adenocarcinoma: Chi Hong Kim, Seung Hoon Kim, Sonya Youngju Park, Jinyoung Yoo, Sung Kyoung Kim, Hoon Kyo Kim; Cancer Res Treat. 2015;47(4):653-660. Published online January 30, 2015; DOI: https://doi.org/10.4143/crt.2014.118

Purpose
Mutation-specific antibodies have recently been developed for identification of epidermal growth factor receptor (EGFR) mutations by immunohistochemistry (IHC). This study was designed to investigate whether the type of specimen (biopsy vs. resection) would make a difference in determining mutation status by IHC, and to evaluate whether biopsies are suitable for detection of mutant EGFR protein.
Materials and Methods
IHC was performed using mutation-specific antibodies for E746-A750 deletion (DEL) and L858R point mutation (L858R) in biopsies and tissue microarrays of resected tumors from 154 patients with pulmonary adenocarcinoma. Results were then compared with DNA sequencing data.
Results
Molecular-based assays detected EGFR mutations in 62 patients (40.3%), including 14 (9.1%) with DEL, and 31 (20.1%) with L858R. IHC with two mutation-specific antibodies showed a homogeneous staining pattern, and correctly identified EGFRmutation status in 89% (137/154). Overall (biopsy/resection) sensitivity, specificity, positive predictive value, and negative predictive value were 75.6% (78.3%/72.7%), 94.5% (90.9%/96.3%), 85% (78.3%/88.9%), and 90.4% (90.9%/89.7%), respectively.
Conclusion
Our data showed that IHC using EGFR mutation–specific antibodies is useful for detection of EGFRmutations with high specificity and good sensitivity not only for resection specimens but also for biopsy materials. Therefore, IHC using EGFRmutation–specific antibodies may preclude a second biopsy procedure to obtain additional tissues for identification of EGFR mutations by molecular assays in biopsies from advanced cancer, particularly when tumor cells in the samples are limited.

Citations

Citations to this article as recorded by

Implications of EGFR expression on EGFR signaling dependency and adaptive immunity against EGFR-mutated lung adenocarcinoma
Masahiro Torasawa, Tatsuya Yoshida, Kouya Shiraishi, Shigehiro Yagishita, Hanako Ono, Yuji Uehara, Jun Miyakoshi, Akiko Tateishi, Yukiko Shimoda Igawa, Ryoko Inaba Higashiyama, Akifumi Mochizuki, Ken Masuda, Yuji Matsumoto, Yuki Shinno, Yusuke Okuma, Yasu
Lung Cancer.2025; 202: 108494. CrossRef
SH3 domain‑binding glutamic acid‑rich protein‑like 3 is associated with hyperglycemia and a poor outcome in Epstein‑Barr virus‑negative gastric carcinoma
Houqiang Li, Lanqing Zheng, Xia Zhang, Xunbin Yu, Guodong Zhong, Xiaoyan Chen, Xin Chen, Linying Chen
Oncology Letters.2024;[Epub] CrossRef
Induction of SUSD2 by STAT3 Activation Is Associated with Tumor Recurrence in HER2-Positive Breast Cancer
Yisun Jeong, Hyungjoo Kim, Daeun You, Soo Youn Cho, Sun Young Yoon, Seok Won Kim, Seok Jin Nam, Jeong Eon Lee, Sangmin Kim
Cells.2024; 14(1): 19. CrossRef
MEK Is a Potential Indirect Target in Subtypes of Head and Neck Cancers
Bianka Gurbi, Diána Brauswetter, Kinga Pénzes, Attila Varga, Tibor Krenács, Kornél Dános, Ede Birtalan, László Tamás, Miklós Csala
International Journal of Molecular Sciences.2023; 24(3): 2782. CrossRef
Effects of EGFR gene mutation on stage 3A lung adenocarcinomas in the clinical decision-making process for mediastinal invasive staging
İsmail Ağababaoğlu, Özgür Ömer Yıldız, Hasan Ersöz, Gökçen Şimşek, Yavuz Selim Sanisoğlu, Nurettin Karaoğlanoğlu
Medical Science and Discovery.2022; 9(1): 44. CrossRef
Dual NGS Comparative Analysis of Liquid Biopsy (LB) and Formalin-Fixed Paraffin-Embedded (FFPE) Samples of Non-Small Cell Lung Carcinoma (NSCLC)
Laura Buburuzan, Maria-Anca Zamfir (Irofei), Carmen Maria Ardeleanu, Alin Horatiu Muresan, Florina Vasilescu, Ariana Hudita, Marieta Costache, Bianca Galateanu, Alexandra Puscasu, Alexandru Filippi, Natalia Motas
Cancers.2022; 14(24): 6084. CrossRef
Role of EGFR and HER-2/NEU Expression in Gall Bladder Carcinoma (GBC)
Chhanda Das, Madhumita Mukhopadhyay, Srijana Subba, Ashis Kumar Saha, Biswanath Mukhopadhyay
Journal of Laboratory Physicians.2021; 13(01): 029. CrossRef
Application of the conventional and novel methods in testing EGFR variants for NSCLC patients in the last 10 years through different regions: a systematic review
Jasmina Obradovic, Jovana Todosijevic, Vladimir Jurisic
Molecular Biology Reports.2021; 48(4): 3593. CrossRef
RETRACTED ARTICLE: AKT3-mediated IWS1 phosphorylation promotes the proliferation of EGFR-mutant lung adenocarcinomas through cell cycle-regulated U2AF2 RNA splicing
Georgios I. Laliotis, Evangelia Chavdoula, Maria D. Paraskevopoulou, Abdul Kaba, Alessandro La Ferlita, Satishkumar Singh, Vollter Anastas, Keith A. Nair, Arturo Orlacchio, Vasiliki Taraslia, Ioannis Vlachos, Marina Capece, Artemis Hatzigeorgiou, Dario Pa
Nature Communications.2021;[Epub] CrossRef
Molecular profiling and utility of cell-free DNA in nonsmall carcinoma of the lung
Moupali Ghosh, Madhumita Mukhopadhyay, Chhanda Das, Surojit Chatterjee, Bidisha Ghosh Naskar
Journal of Cancer Research and Therapeutics.2021; 17(6): 1389. CrossRef
Phenotypic Characterization of Circulating Lung Cancer Cells for Clinically Actionable Targets
Arutha Kulasinghe, Joanna Kapeleris, Carolina Cooper, Majid Ebrahimi Warkiani, Kenneth O’Byrne, Chamindie Punyadeera
Cancers.2019; 11(3): 380. CrossRef
Analysis of Genetic Alterations in Tunisian Patients with Lung Adenocarcinoma
Dhoha Dhieb, Imen Belguith, Laura Capelli, Elisa Chiadini, Matteo Canale, Sara Bravaccini, Ilhem Yangui, Ons Boudawara, Rachid Jlidi, Tahya Boudawara, Daniele Calistri, Leila Ammar Keskes, Paola Ulivi
Cells.2019; 8(6): 514. CrossRef
Intratumour heterogeneity of p53 expression; causes and consequences
Yuezhen Xue, Boris San Luis, David P Lane
The Journal of Pathology.2019; 249(3): 274. CrossRef
Update on EGFR Mutational Testing and the Potential of Noninvasive Liquid Biopsy in Non–Small-cell Lung Cancer
Edward Kim, Rebecca Feldman, Ignacio I. Wistuba
Clinical Lung Cancer.2018; 19(2): 105. CrossRef
Any Place for Immunohistochemistry within the Predictive Biomarkers of Treatment in Lung Cancer Patients?
Véronique Hofman, Sandra Lassalle, Coraline Bence, Elodie Long-Mira, Sacha Nahon-Estève, Simon Heeke, Virginie Lespinet-Fabre, Catherine Butori, Marius Ilié, Paul Hofman
Cancers.2018; 10(3): 70. CrossRef
EGFR mutation status in Tunisian non-small-cell lung cancer patients evaluated by mutation-specific immunohistochemistry
Zohra Mraihi, Jihen Ben Amar, Hend Bouacha, Soumaya Rammeh, Lamia Hila
BMC Pulmonary Medicine.2018;[Epub] CrossRef
Immunohistochemistry for EGFR Mutation Detection in Non–Small-Cell Lung Cancer
Nina Turnšek Hitij, Izidor Kern, Aleksander Sadikov, Lea Knez, Karmen Stanič, Matjaž Zwitter, Tanja Cufer
Clinical Lung Cancer.2017; 18(3): e187. CrossRef
Mutations of the Epidermal Growth Factor Receptor Gene in Triple-Negative Breast Cancer
Aeri Kim, Min Hye Jang, Soo Jung Lee, Young Kyung Bae
Journal of Breast Cancer.2017; 20(2): 150. CrossRef
Detection of epidermal growth factor receptor mutations in lung adenocarcinoma cytological specimens by immunocytochemistry
Masami Yoshida, Tadasuke Nagatomo, Takafumi Ohnishi, Mayumi Kawashima, Akira Naitoh, Eiichi Morii
Molecular and Clinical Oncology.2017;[Epub] CrossRef
Diagnostic algorithm for detection of targetable driver mutations in lung adenocarcinomas: Comprehensive analyses of 205 cases with immunohistochemistry, real-time PCR and fluorescence in situ hybridization methods
Hua-Lin Kao, Yi-Chen Yeh, Chin-Hsuan Lin, Wei-Fang Hsu, Wen-Yu Hsieh, Hsiang-Ling Ho, Teh-Ying Chou
Lung Cancer.2016; 101: 40. CrossRef
LYN expression predicts the response to dasatinib in a subpopulation of lung adenocarcinoma patients
Yu Jin Kim, Sungyoul Hong, Minjung Sung, Min Jeong Park, Kyungsoo Jung, Ka-Won Noh, Doo-Yi Oh, Mi-Sook Lee, Ensel Oh, Young Kee Shin, Yoon-La Choi
Oncotarget.2016; 7(50): 82876. CrossRef

14,953 View
117 Download
26 Web of Science
21 Crossref

Expression of Transforming Growth Factor beta1 and E-Cadherin Proteins in Pulmonary Adenocarcinoma: Its Significance in Tumor Progression: Chi Hong Kim, Sonya Youngju Park, Jinyoung Yoo; Cancer Res Treat. 2013;45(2):118-125. Published online June 30, 2013; DOI: https://doi.org/10.4143/crt.2013.45.2.118

Abstract PDF PubReader ePub

PURPOSE
This study was conducted in order to investigate the significance of transforming growth factor beta1 (TGFbeta1) and E-cadherin proteins in tumor progression of lung adenocarcinoma and to evaluate their differential expression in association with morphologic characteristics.
MATERIALS AND METHODS
A total of 65 pulmonary adenocarcinomas were reclassified according to the new classification system proposed by the International Association for the Study of Lung Cancer, American Thoracic Society, and European Respiratory Society. Tumor samples from 20 adenocarcinomas in situ (AIS, formerly bronchioloalveolar carcinoma [BAC]), 9 minimally invasive adenocarcinomas (MIA, formerly BAC with < or = 5 mm invasion), 17 lepidic predominant adenocarcinomas (LPA, formerly mixed adenocarcinoma showing nonmucinous BAC features with >5 mm invasion), and 19 invasive adenocarcinomas with no BAC features were analyzed by immunohistochemistry for expression of TGFbeta1 and E-cadherin proteins.
RESULTS
TGFbeta1 expression was detected in 46% (21/46) of noninvasive elements and 87% (39/45) of invasive elements (p=0.001). E-Cadherin expression was less frequent in invasive components than in noninvasive components (38% vs. 65%, p=0.009). Negative correlation was identified between TGFbeta1 expression and E-cadherin expression in noninvasive elements (p=0.022). More importantly, significantly higher frequency of TGFbeta1 expression was observed in noninvasive components of LPA (14/17, 82%), compared with those of either AIS (5/20, 25%) or MIA (2/9, 22%) (p=0.008).
CONCLUSION
Our data indicate involvement of both TGFbeta1 and E-cadherin proteins in tumor progression of pulmonary adenocarcinoma. It is noteworthy that TGFbeta1 up-regulation precedes alveolar destruction by invasion of tumor cells. TGFbeta1 may thus have the potential to improve lung adenocarcinoma diagnostics and therapeutics.

Citations

Citations to this article as recorded by

Aberrant N-cadherin expression in cancer
Zhan-Qi Cao, Zhi Wang, Ping Leng
Biomedicine & Pharmacotherapy.2019; 118: 109320. CrossRef
High FDG uptake on PET is associated with negative cell-to-cell adhesion molecule E-cadherin expression in lung adenocarcinoma
Kotaro Higashi, Yoshimichi Ueda, Miyako Shimasaki, Yasuhito Ishigaki, Yuka Nakamura, Manabu Oguchi, Tsutomu Takegami, Naoto Watanabe
Annals of Nuclear Medicine.2017; 31(8): 590. CrossRef
17‐AAG suppresses growth and invasion of lung adenocarcinoma cells via regulation of the LATS1/YAP pathway
Xiang‐Yun Ye, Qing‐Quan Luo, Yun‐Hua Xu, Nai‐Wang Tang, Xiao‐Min Niu, Zi‐Ming Li, Sheng‐Ping Shen, Shun Lu, Zhi‐Wei Chen
Journal of Cellular and Molecular Medicine.2015; 19(3): 651. CrossRef
F-box protein complex FBXL19 regulates TGFβ1-induced E-cadherin down-regulation by mediating Rac3 ubiquitination and degradation
Su Dong, Jing Zhao, Jianxin Wei, Rachel K Bowser, Andrew Khoo, Zhonghui Liu, James D Luketich, Arjun Pennathur, Haichun Ma, Yutong Zhao
Molecular Cancer.2014;[Epub] CrossRef
High p-Smad2 expression in stromal fibroblasts predicts poor survival in patients with clinical stage I to IIIA non-small cell lung cancer
Yongbing Chen, Pengfei Xing, Yuanyuan Chen, Li Zou, Yongsheng Zhang, Feng Li, Xueguan Lu
World Journal of Surgical Oncology.2014;[Epub] CrossRef
Brain Metastases from Lung Cancer Show Increased Expression of DVL1, DVL3 and Beta-Catenin and Down-Regulation of E-Cadherin
Anja Kafka, Davor Tomas, Vili Beroš, Hrvoje Pećina, Martina Zeljko, Nives Pećina-Šlaus
International Journal of Molecular Sciences.2014; 15(6): 10635. CrossRef
TGF-β Suppresses COX-2 Expression by Tristetraprolin-Mediated RNA Destabilization in A549 Human Lung Cancer Cells
Soyeong Kang, Ahrum Min, Seock-Ah Im, Sang-Hyun Song, Sang Gyun Kim, Hyun-Ah Kim, Hee-Jun Kim, Do-Youn Oh, Hyun-Soon Jong, Tae-You Kim, Yung-Jue Bang
Cancer Research and Treatment.1970; 47(1): 101. CrossRef

10,756 View
48 Download
7 Crossref

Immunohistochemical Expression of DCUN1D1 in Non-small Cell Lung Carcinoma: Its Relation to Brain Metastasis: Jinyoung Yoo, Seong-Hak Lee, Kwang-Il Lym, Sonya Youngju Park, Seung-Ho Yang, Chang-Young Yoo, Ji-Han Jung, Seok-Jin Kang, Chang-Suk Kang; Cancer Res Treat. 2012;44(1):57-62. Published online March 31, 2012; DOI: https://doi.org/10.4143/crt.2012.44.1.57

Abstract PDF PubReader ePub

PURPOSE
Non-small cell lung carcinoma (NSCLC) comprises 75-85% of all lung cancers, and approximately 25% of all NSCLC patients develop brain metastasis. There are no reliable markers for predicting in which patients this metastasis will occur. DCUN1D1, also known as squamous cell carcinoma-related oncogene, is associated with tumor progression and poor outcomes in NSCLC. The objective of this study was to investigate the role of DCUN1D1 expression in cases of brain metastasis due to NSCLC.
MATERIALS AND METHODS
Primary tumor samples from a total of 71 cases of NSCLC, either with (n=40) or without (n=31) brain metastasis, were evaluated for DCUN1D1 expression by immunohistochemistry analysis.
RESULTS
DCUN1D1 expression was detected in 16 patients (23%) and tended to correlate with T classification (15% of T1-2 tumors vs. 30% of T3-4 tumors, p=0.083). DCUN1D1 expression was significantly associated with tumor stage. It was observed in none of the patients with stage I disease, 10% of those with stage II disease, and 29% with stage III disease (p=0.009). In addition, 14 of 16 DCUN1D1-positive patients resulted in brain metastasis (p=0.01). The odds ratio of brain metastasis for patients with DCUN1D1 expression was 3.112 (p=0.009).
CONCLUSION
DCUN1D1 expression may play a role in tumor progression and development of brain metastasis in patients with NSCLC. Evaluation of DCUN1D1 expression may provide assistance in identifying those patients who are at higher risk for brain metastasis.

Citations

Citations to this article as recorded by

DCUN1D1 and neddylation: Potential targets for cancer therapy
Juliano D. Paccez, Chiara L.M. Foret, Jaira F. de Vasconcellos, Lara Donaldson, Luiz F. Zerbini
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease.2024; 1870(7): 167308. CrossRef
Research progress of LSD1-based dual-target agents for cancer therapy
Xiaojuan Yang
Bioorganic & Medicinal Chemistry.2024; 101: 117651. CrossRef
Inhibition of DCUN1D1 attenuates periodontitis by suppressing NF-κB signaling
Li Zou, Zhijian Su, Chao Pan, Honghui Xie, Shuangjing Li, Jian Qin
Odontology.2024; 112(4): 1266. CrossRef
Discovery of WS-384, a first-in-class dual LSD1 and DCN1-UBC12 protein-protein interaction inhibitor for the treatment of non-small cell lung cancer
Anqi Li, Ting Ma, Shuai Wang, Yueyang Guo, Qianqian Song, Hongmin Liu, Bin Yu, Siqi Feng
Biomedicine & Pharmacotherapy.2024; 173: 116240. CrossRef
YY1 mediated DCUN1D5 transcriptional activation promotes triple-negative breast cancer progression by targeting FN1/PI3K/AKT pathway
Yuxiang Lin, Yan Li, Xiaobin Chen, Xuan Jin, Meichen Jiang, Han Xiao, Lili Chen, Minyan Chen, Wenzhe Zhang, Hanxi Chen, Qian Nie, Rongrong Guo, Wenhui Guo, Fangmeng Fu, Chuan Wang
Biology Direct.2024;[Epub] CrossRef
A comprehensive review on DCN1 protein, inhibitors and their therapeutic applications
Zhangxu He, Ziqiao Yuan, Feifei Yang, Jingyu Zhang, Wen Zhao, Tingting Qin, Xiaoke Zheng, Liying Ma
International Journal of Biological Macromolecules.2024; 277: 134541. CrossRef
Unmasking the Intruder: A Case of Lung Carcinoma Mimicking As Glioma
Joana Christopher, Thanka Johnson, Anbukkarasi Kannan, Santhanam Rengarajan
Cureus.2024;[Epub] CrossRef
DCUN1D1 Is an Essential Regulator of Prostate Cancer Proliferation and Tumour Growth That Acts through Neddylation of Cullin 1, 3, 4A and 5 and Deregulation of Wnt/Catenin Pathway
Akhona Vava, Juliano D. Paccez, Yihong Wang, Xuesong Gu, Manoj K. Bhasin, Michael Myers, Nelson C. Soares, Towia A. Libermann, Luiz F. Zerbini
Cells.2023; 12(15): 1973. CrossRef
Advances in the Biology and Molecular Study of Brain Metastasis from Non-Small Cell Lung Cancer
小雯邱
Advances in Clinical Medicine.2022; 12(06): 5561. CrossRef
Development of phenyltriazole thiol-based derivatives as highly potent inhibitors of DCN1-UBC12 interaction
Wenjuan Zhou, Chenhao Xu, Guanjun Dong, Hui Qiao, Jing Yang, Hongmin Liu, Lina Ding, Kai Sun, Wen Zhao
European Journal of Medicinal Chemistry.2021; 217: 113326. CrossRef
Evidence for frequent concurrent DCUN1D1, FGFR1, BCL9 gene copy number amplification in squamous cell lung cancer
Ilenia Chatziandreou, Adriana Psaraki, Konstantinos Paschidis, Andreas C. Lazaris, Angelica A. Saetta
Pathology - Research and Practice.2021; 221: 153412. CrossRef
DCUN1D1 facilitates tumor metastasis by activating FAK signaling and up-regulates PD-L1 in non-small-cell lung cancer
Jing Li, Tao Yu, Mingxia Yan, Xiao Zhang, Li Liao, Miaoxin Zhu, Hechun Lin, Hongyu Pan, Ming Yao
Experimental Cell Research.2019; 374(2): 304. CrossRef
Development of Highly Potent, Selective, and Cellular Active Triazolo[1,5-a]pyrimidine-Based Inhibitors Targeting the DCN1–UBC12 Protein–Protein Interaction
Shuai Wang, Lijie Zhao, Xiao-Jing Shi, Lina Ding, Linlin Yang, Zhi-Zheng Wang, Dandan Shen, Kai Tang, Xiao-Jing Li, MAA Mamun, Huiju Li, Bin Yu, Yi-Chao Zheng, Shaomeng Wang, Hong-Min Liu
Journal of Medicinal Chemistry.2019; 62(5): 2772. CrossRef
Expression of DCUN1D1 in laryngeal squamous cell carcinoma and its inhibiting effect on TU‐177 cells after interfered by RNA
Jing Liu, Yu Shuang, Chao Li, Xuan Zhou, Yongwang Huang, Lun Zhang
Clinical and Experimental Pharmacology and Physiology.2018; 45(5): 461. CrossRef
Discovery of an Orally Bioavailable Inhibitor of Defective in Cullin Neddylation 1 (DCN1)-Mediated Cullin Neddylation
Jared T. Hammill, Deepak Bhasin, Daniel C. Scott, Jaeki Min, Yizhe Chen, Yan Lu, Lei Yang, Ho Shin Kim, Michele C. Connelly, Courtney Hammill, Gloria Holbrook, Cynthia Jeffries, Bhuvanesh Singh, Brenda A. Schulman, R. Kiplin Guy
Journal of Medicinal Chemistry.2018; 61(7): 2694. CrossRef
MicroRNA‑302 inhibits cell migration and invasion in cervical cancer by targeting DCUN1D1
Yongjie Jiang, Ruijie Hou, Shaoping Li, Shaoru Li, Ge Dang
Experimental and Therapeutic Medicine.2018;[Epub] CrossRef
MicroRNA-520b Functions as a Tumor Suppressor in Colorectal Cancer by Inhibiting Defective in Cullin Neddylation 1 Domain Containing 1 (DCUN1D1)
Jing Xiao, Guang Li, Jingyu Zhou, Shalong Wang, Dongcai Liu, Guoshun Shu, Jianping Zhou, Feng Ren
Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics.2018; 26(4): 593. CrossRef
MicroRNA-195 inhibits growth and invasion of laryngeal carcinoma cells by directly targeting DCUN1D1
Yu Shuang, Chao Li, Xuan Zhou, Yongwang Huang, Lun Zhang
Oncology Reports.2017; 38(4): 2155. CrossRef
Osteosarcoma tissues and cell lines from patients with differing serum alkaline phosphatase concentrations display minimal differences in gene expression patterns
L. C. de Sá Rodrigues, K. E. Holmes, V. Thompson, C. M. Piskun, S. E. Lana, M. A. Newton, T. J. Stein
Veterinary and Comparative Oncology.2016;[Epub] CrossRef
Ubiquitin-specific protease 4 controls metastatic potential through β-catenin stabilization in brain metastatic lung adenocarcinoma
Su Jin Hwang, Hye Won Lee, Hye Ree Kim, Hong Lee, Chang Hoon Shin, Sun-Il Yun, Dong Heon Lee, Duk-Hwan Kim, Kyeong Kyu Kim, Kyeung Min Joo, Hyeon Ho Kim
Scientific Reports.2016;[Epub] CrossRef
Blood-brain Barrier Remodeling during Brain Metastasis Formation
Jagoda K Wrobel, Michal Toborek
Molecular Medicine.2016; 22(1): 32. CrossRef
MicroRNA-218 inhibits EMT, migration and invasion by targeting SFMBT1 and DCUN1D1 in cervical cancer
Zhaojing Jiang, Qiancheng Song, Rong Zeng, Jing Li, Jingyu Li, Xiaochun Lin, Xing Chen, Jiren Zhang, Yanfang Zheng
Oncotarget.2016; 7(29): 45622. CrossRef
Value of Oncogenes for the Prediction of Brain Metastases at Initial Diagnosis: A Review of Published Data
Qian Huang, Xuenong Ouyang
The International Journal of Biological Markers.2014; 29(4): 291. CrossRef
The molecular biology of lung cancer brain metastasis: an overview of current comprehensions and future perspectives
Masaki Hanibuchi, Sun-Jin Kim, Isaiah J. Fidler, Yasuhiko Nishioka
The Journal of Medical Investigation.2014; 61(3.4): 241. CrossRef
Predictive biochemical-markers for the development of brain metastases from lung cancer: Clinical evidence and future directions
Qian Huang, Xuenong Ouyang
Cancer Epidemiology.2013; 37(5): 703. CrossRef
Coamplification and Cooperation: Toward Identifying Biologically Relevant Oncogenes
Guochang Huang, Bhuvanesh Singh
Clinical Cancer Research.2013; 19(20): 5549. CrossRef

10,335 View
59 Download
26 Crossref

Prognostic Role of Rb, p16, Cyclin D1 Proteins in Soft Tissue Sarcomas: Byoung Yong Shim, Jinyoung Yoo, Yeon-Soo Lee, Young Sun Hong, Hoon-Kyo Kim, Jin-Hyoung Kang; Cancer Res Treat. 2010;42(3):144-150. Published online September 30, 2010; DOI: https://doi.org/10.4143/crt.2010.42.3.144

Abstract PDF PubReader ePub

Purpose

The aim of this study was to determine the expressions of Rb, p16, and cyclin D1 in soft tissue sarcomas, and we also wanted to identify the prognostic factors according to the clinicalpathologic features.

Materials and Methods

We reviewed the charts and radiographic films of 66 sarcoma patients. Tissue samples were collected from these patients. Immunochemistry was performed using formalin-fixed, paraffin-embedded tissue samples to examine the expressions of p16, Rb, and cyclin D1 proteins.

Results

The median duration of overall survival was 47.8 months (range, 20.0 to 70.7 months) and the 5 years survival rate was 39%. As for the correlation between the degree of immunohistochemical staining for Rb protein and the histological tumor grades, there was a significant difference with a p-value of 0.019. However, no significant correlation was shown for p16 and cyclin D1. The overall survival duration of the Rb negative group (staining cell <20%) and the heterogeneous group (cell staining 20 to 80%) was 53.5±6.6 months and the overall survival duration of the Rb homogeneous group was 18.3±6.4 months, and there was a significant difference with a p-value of 0.016. However, no significant difference was shown between the survival rate according to the p16 and cyclin D1 expressions. On the multivariate analysis that was done with Rb, p16, the tumor size, grade and site, and patient age, the Rb gene expression was the most significant independent prognostic factor with a risk ratio of 3.01 (p=0.04).

Conclusion

The expression of Rb protein was correlated with the histologic grade and overall survival of patients with soft tissue sarcomas.

Citations

Citations to this article as recorded by

Immunohistochemical Expression of p16 and CDK4 in Soft Tissue Tumors
Mala Sagar, Rita Yadav, Pankaj Deval, Madhu Kumar, Malti K Maurya, Sumaira Qayoom
Cureus.2023;[Epub] CrossRef
Carcinosarcoma, a Rare Malignant Neoplasm of the Pancreas
Jaffar Khan, Liang Cheng, Michael G. House, Shunhua Guo
Current Oncology.2021; 28(6): 5295. CrossRef
Co-expression of MDM2 and CDK4 in transformed human mesenchymal stem cells causes high-grade sarcoma with a dedifferentiated liposarcoma-like morphology
Yu Jin Kim, Mingi Kim, Hyung Kyu Park, Dan Bi Yu, Kyungsoo Jung, Kyoung Song, Yoon-La Choi
Laboratory Investigation.2019; 99(9): 1309. CrossRef
Prognostic significance of p16INK4a alteration in soft tissue sarcomas: A meta-analysis
Gang Lin, Yue Lou
Indian Journal of Cancer.2017; 54(3): 580. CrossRef
GATA3 Expression Is a Poor Prognostic Factor in Soft Tissue Sarcomas
Toshiaki Haraguchi, Hiroaki Miyoshi, Koji Hiraoka, Shintaro Yokoyama, Yukinao Ishibashi, Toshihiro Hashiguchi, Koutaro Matsuda, Tetsuya Hamada, Takahiro Okawa, Naoto Shiba, Koichi Ohshima, Ichiro Aoki
PLOS ONE.2016; 11(6): e0156524. CrossRef
Sarcoma spreads primarily through the vascular system: are there biomarkers associated with vascular spread?
Elisabetta Pennacchioli, Giulio Tosti, Massimo Barberis, Tommaso M. De Pas, Francesco Verrecchia, Claudia Menicanti, Alessandro Testori, Giovanni Mazzarol
Clinical & Experimental Metastasis.2012; 29(7): 757. CrossRef

10,393 View
65 Download
6 Crossref

Case Report

Sequential Responses of Adenocarcinoma of the Lung to Erlotinib after Gefitinib in Never Smoker Korean Woman: Hoon-Kyo Kim, Myeong Im Ahn, Jinyoung Yoo, Chi Hong Kim, Hong-Jun Yang, Byoung Yong Shim; Cancer Res Treat. 2007;39(1):37-39. Published online March 31, 2007; DOI: https://doi.org/10.4143/crt.2007.39.1.37

Abstract PDF PubReader ePub

A patient with adenocarcinoma of the lung was treated sequentially using two kinds of EGFR tyrosine kinase inhibitors, gefitinib and erlotinib. The patient was a 73-year-old female who received gefitinib as a second line treatment, which resulted in a partial response with response duration of 6 months. After progression of the disease, the patient received erlotinib, which resulted in partial response again with response duration of 11.5 months. This observation suggests that treatment with erlotinib may be effective in patients who develop progressive disease after a primary treatment with gefitinib following an initial response.

Citations

Citations to this article as recorded by

Erlotinib usage after prior treatment with gefitinib in advanced non-small cell lung cancer: A clinical perspective and review of published literature
Navneet Singh
World Journal of Clinical Oncology.2014; 5(5): 858. CrossRef
Successful Rechallenge with Gefitinib for an Initial Erlotinib-Responder with Advanced Lung Adenocarcinoma
Sung Chul Hong, Yun Su Sim, Jin Hwa Lee, Yon Ju Ryu, Jung Hyun Chang
Tuberculosis and Respiratory Diseases.2011; 71(4): 286. CrossRef

10,101 View
61 Download
2 Crossref

Original Articles

The Safety and Efficacy of Second-line Single Docetaxel (75 mg/m²) Therapy in Advanced Non-Small Cell Lung Cancer Patients who were Previously Treated with Platinum-based Chemotherapy: Byoung Yong Shim, Chi Hong Kim, So Hyang Song, Meyung Im Ahn, Eun Jung Hong, Sung Whan Kim, Suzy Kim, Min Seop Jo, Deog Gon Cho, Kyu Do Cho, Jinyoung Yoo, Hoon-Kyo Kim; Cancer Res Treat. 2005;37(6):339-343. Published online December 31, 2005; DOI: https://doi.org/10.4143/crt.2005.37.6.339

Abstract PDF PubReader ePub

Purpose

When used in the second-line setting, single-agent chemotherapy has produced response rates of more than 10% or median survival times greater than 4 months. We studied the safety and efficacy of using second-line single docetaxel (75 mg/m²) for advanced NSCLC patients who were previously treated with platinum-based chemotherapy in Korea.

Materials and Methods

Thirty-three patients with advanced NSCLC received chemotherapy from May 2002 to January 2005. We retrospectively reviewed the charts of these patients. The patients received 75 mg/m² of doxetaxel on day 1 and this was repeated at 3-week intervals.

Results

The median age was 63 years (range: 42~77 years); 16 patients had adenocarcinoma and 8 patients had squamous cell carcinoma. The median number of cycles was 4 (range: 1~7 cycles). Of the 33 patients, 6 patients had partial responses, 13 patients had stable disease and 14 patients had progressive disease. The response rate was 18.2%. The median overall survival was 11 months (range: 7~15 months), and the median progression free survival was 5 months (range: 3~7 months). The median response duration was 5 months (range: 4~9 months). A total of 137 cycles were evaluated for toxicity. We observed grade 3 or 4 neutropenia in 79 cycles (57.6%), grade 3 or 4 leukopenia in 46 cycles (33.6%), and grade 3 febrile neutropenia in 2 cycles (1.5%). The median nadir day was day 9 (range: day 5~19), and the median number of G-CSF injections was 2 (range: 0~6). The most common non-hematologic toxicities were myalgia/arthralgia and neurotoxicity, but any grade 3 or 4 non-hematologic toxicity was not observed. The major toxicity of this therapy was neutropenia. The absolute neutrophil count decreased relatively rapidly, but neutropenic fever or related infection was rare. There were no treatment-related deaths.

Conclusion

These results revealed a satisfactory response rate (18.2%) with using docetaxel as the second-line chemotherapy for NSCLC. The second-line docetaxel was an active and well-tolerated regimen in patients with advanced NSCLC pretreated with platinum-based chemotherapy.

Citations

Citations to this article as recorded by

Sintilimab plus docetaxel as second-line therapy of advanced non-small cell lung cancer without targetable mutations: a phase II efficacy and biomarker study
Yongchang Zhang, Lianxi Song, Liang Zeng, Yi Xiong, Li Liu, Chunhua Zhou, Haiyan Yang, Zhan Wang, Qing Xia, Wenjuan Jiang, Qinqin Xu, Nong Yang
BMC Cancer.2022;[Epub] CrossRef
Randomized phase II study comparing weekly docetaxel-cisplatin vs. gemcitabine-cisplatin in elderly or poor performance status patients with advanced non-small cell lung cancer
JoungSoon Jang, Hoon-Kyo Kim, Byoung Chul Cho, Kyung Hee Lee, Hwan-Jung Yun, In Sook Woo, Hong Suk Song, Hun-Mo Ryoo, Chi-Hong Kim, Der-Sheng Sun, Jong Wook Shin
Cancer Chemotherapy and Pharmacology.2017; 79(5): 873. CrossRef
Treatment of taxane acute pain syndrome (TAPS) in cancer patients receiving taxane-based chemotherapy—a systematic review
Ricardo Fernandes, Sasha Mazzarello, Habeeb Majeed, Stephanie Smith, Risa Shorr, Brian Hutton, Mohammed FK Ibrahim, Carmel Jacobs, Michael Ong, Mark Clemons
Supportive Care in Cancer.2016; 24(4): 1583. CrossRef
Weekly Low-Dose Docetaxel for Salvage Chemotherapy in Pretreated Elderly or Poor Performance Status Patients with Non-small Cell Lung Cancer
Keun-Wook Lee, Joo Han Lim, Jee Hyun Kim, Choon-Taek Lee, Jong Seok Lee
Journal of Korean Medical Science.2008; 23(6): 992. CrossRef
Docetaxel Monotherapy as Second-Line Treatment for Pretreated Advanced Non-Small Cell Lung Cancer Patients
Yoon Ho Ko, Myung Ah Lee, Yeong Seon Hong, Kyung Shik Lee, Hyun Jin Park, Ie Ryung Yoo, Yeon Sil Kim, Young Kyoon Kim, Keon Hyun Jo, Young Pil Wang, Kyo Young Lee, Jin Hyoung Kang
The Korean Journal of Internal Medicine.2007; 22(3): 178. CrossRef

10,603 View
68 Download
5 Crossref

Expression of Matrix Metalloproteinase-9 Correlates with Poor Prognosis in Human Malignant Fibrous Histiocytoma: Jinyoung Yoo, Ji Han Jung, Seok Jin Kang, Chang Suk Kang; Cancer Res Treat. 2004;36(6):384-388. Published online December 31, 2004; DOI: https://doi.org/10.4143/crt.2004.36.6.384

Abstract PDF PubReader ePub

Purpose

92 kDa matrix metalloproteinase-9 (MMP-9) is believed to play an important role in degrading the matrix and basement membrane, contributing to the invasion and metastasis of malignant solid tumors. However, little is known about its involvement in a malignant fibrous histiocytoma. The aim of this study was to investigate the expression of MMP-9 and to correlate its expression with clinicopathologic parameters in human malignant fibrous histiocytomas.

Materials and Methods

Archival tumor tissues from 20 patients with a malignant fibrous histiocytoma were analyzed by immunohistochemistry for the expression of MMP-9. Clinical information was obtained through the computerized retrospective database from the tumor registry.

Results

Seventeen of 20 (85%) tumors showed a positive reaction for MMP-9. MMP-9 activity was inversely correlated with patients' survival time (p=.011). There was no significant correlation between the activated MMP-9 expression and all the other clinicopathologic variables.

Conclusion

Our data demonstrate that MMP-9 activation is likely to occur in human malignant fibrous histiocytomas. It is also noteworthy that the expression of MMP-9 may aid in predicting patients' poor prognosis.

Citations

Citations to this article as recorded by

Identification and characterization of stromal-like cells with CD207+/low CD1a+/low phenotype derived from histiocytic lesions – a perspective in vitro model for drug testing
Agnieszka Śmieszek, Klaudia Marcinkowska, Zofia Małas, Mateusz Sikora, Martyna Kępska, Beata A. Nowakowska, Marta Deperas, Marta Smyk, Carlos Rodriguez-Galindo, Anna Raciborska
BMC Cancer.2024;[Epub] CrossRef
Differential expression of mitotic regulators and tumor microenvironment influences the regional growth pattern of solid sarcoma along the cranio-caudal axis
Sukalpa Chattopadhyay, Malay Chaklader, Ritam Chatterjee, Aditya Law, Sujata Law
Experimental Cell Research.2016; 340(1): 91. CrossRef
Expression of matrix metalloproteinase-9 and significance of a macrophage assay in eosinophilic granuloma
Manal Mohamed Zyada
Annals of Diagnostic Pathology.2009; 13(6): 367. CrossRef

8,494 View
47 Download
3 Crossref

Expression of c-kit and p53 in Non-small Cell Lung Cancers: Jinyoung Yoo, Chi Hong Kim, So Hyang Song, Byoung Yong Shim, Youn Ju Jeong, Meyung Im Ahn, Sung Whan Kim, Deog Gon Cho, Min Seop Jo, Kyu Do Cho, Hong Joo Cho, Hoon-Kyo Kim; Cancer Res Treat. 2004;36(3):167-172. Published online June 30, 2004; DOI: https://doi.org/10.4143/crt.2004.36.3.167

Abstract PDF PubReader ePub

Purpose

Increasing experimental evidence indicates that abnormal expression of c-kit may be implicated in the pathogenesis of a variety of solid tumors. It has been reported that over 70% of small cell lung cancer (SCLC) contain the c-kit receptor. In the present study, a c-kit analysis has been extended to non-small cell lung cancer (NSCLC). The expressions of p53, vascular endothelial growth factor (VEGF) and cd34, in addition to c-kit, were evaluated to investigate the correlations between these proteins and to determine their potential relationships with the clinicopathological data.

Materials and Methods

Paraffin-embedded tumor sections, obtained from 147 patients with NSCLC, were immunohistochemically investigated using anti-c-kit, anti-p53, anti-VEGF and anti-cd34 antibodies.

Results

c-kit was expressed in 40 (27%) of the tumors examined: 27% of the adenocarcinomas, 27% of the squamous cell carcinomas and 29% of the undifferentiated carcinomas. p53 and VEG F immunoreactivities were present in 107 (73%) and 110 (75%) carcinomas, respectively. Anti-cd34 was negative in all samples. No associations were established among these proteins. The c-kit, however, showed a strong correlation with the T factor: T1 (n=11), 0%; T2 (n=49), 16% and T3 (n=87), 37% (p=.006).

Conclusion

It is suggested that in NSCLC c-kit is expressed relatively frequently and may become a therapeutic target for the patients with inoperable or recurrent c-kit positive tumors. The alterations in p53 probably constitute an early event, whereas the activated c-kit may contribute to tumor progression.

Citations

Citations to this article as recorded by

Clinical and Prognostic Significance of CD117 in Non-Small Cell Lung Cancer: A Systemic Meta-Analysis
Ying Su, Ru Chen, Zhongcheng Han, Rong Xu, Lili Ma, Reyina Wufuli, Hongbo Liu, Fang Wang, Lei Ma, Rui Chen, Jiang Liu
Pathobiology.2021; 88(4): 267. CrossRef
A review of predictive, prognostic and diagnostic biomarkers for non-small-cell lung cancer: towards personalised and targeted cancer therapy
Ernest Osei, Julia Lumini, Dinindu Gunasekara, Beverley Osei, Akua Asare, Raymond Laflamme
Journal of Radiotherapy in Practice.2020; 19(4): 370. CrossRef
Design, synthesis and anti-cancer activity of pyrrole-imidazole polyamides through target-downregulation of c-kit gene expression
Mi Zhang, Jing Liang, Shi-Kun Jiang, Ling Xu, Yan-Ling Wu, Annoor Awadasseid, Xiao-Yin Zhao, Xu-Qiong Xiong, Hiroshi Sugiyama, Wen Zhang
European Journal of Medicinal Chemistry.2020; 207: 112704. CrossRef
Relative influence of c-Kit expression and epidermal growth factor receptor gene amplification on survival in patients with non-small cell lung cancer
HUI XIAO, JUAN WANG, YANAN LIU, LI LI
Oncology Letters.2014; 8(2): 582. CrossRef
Protein Kinase C-δ–Mediated Recycling of Active KIT in Colon Cancer
Misun Park, Won Kyu Kim, Meiying Song, Minhee Park, Hyunki Kim, Hye Jin Nam, Sung Hee Baek, Hoguen Kim
Clinical Cancer Research.2013; 19(18): 4961. CrossRef

9,163 View
62 Download
5 Crossref

The Expression of c-myc, bcl-2 and p53 Proteins in Adenocarcinomas of Lung: Jinyoung Yoo, Ji Han Jung, Hyun Joo Choi, Seok Jin Kang, Chang Suk Kang; Cancer Res Treat. 2004;36(2):146-150. Published online April 30, 2004; DOI: https://doi.org/10.4143/crt.2004.36.2.146

Abstract PDF PubReader ePub

Purpose

c-myc, bcl-2 and p53 are known to regulate apoptosis. There has been growing interest in analyzing their contribution to the pathogenesis and prognosis in a variety of human cancers. This study was undertaken to investigate the expression of these proteins in pulmonary adenocarcinomas and to determine their relationship with clinicopathologic parameters and survival.

Materials and Methods

Archival tumor tissues from 61 patients with adenocarcinoma of lung were analyzed by immunohistochemistry for the expression of c-myc, bcl-2 and p53 proteins. Clinical information was obtained through the computerized retrospect database from the tumor registry.

Results

Of 61 patients, 32 were men and 29 women with the median age 63 years. 4 had stage I disease, 2 had stage II disease and 55 had stage III disease. The expression of c-myc protein was identified in 13% (8/61) tumors, bcl-2 protein was detected in 1.6% tumors (1/61) and p53 was detected in 77% (47/71) tumors. The association of the expression of c-myc, bcl-2 and p53 was not detected. The survival time was longer in patients expressing c-myc protein than in patients without the c-myc protein expression (p=.045). Neither bcl-2 nor p53 showed the correlation to clinicopathologic variables.

Conclusion

Our data suggest the involvement of p53 alteration in the pathogenesis of lung adenocarcinoma. The c-myc expression in some tumors indicates that c-myc alone may not contribute critically to the development and/or the progression of these tumors. It, however, correlated to the survival time, suggesting the c-myc expression as a favorable prognostic factor possibly through the apoptosis pathway.

Citations

Citations to this article as recorded by

The transcriptional repression activity of STAF65γ is facilitated by promoter tethering and nuclear import of class IIa histone deacetylases
Feng-Shu Hsieh, Nai-Tzu Chen, Ya-Li Yao, Shi-Yun Wang, Jeremy J.W. Chen, Chien-Chen Lai, Wen-Ming Yang
Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms.2014; 1839(7): 579. CrossRef
Expression of Matrix Metalloproteinase-9 Correlates with Poor Prognosis in Human Malignant Fibrous Histiocytoma
Jinyoung Yoo, Ji Han Jung, Seok Jin Kang, Chang Suk Kang
Cancer Research and Treatment.2004; 36(6): 384. CrossRef

8,115 View
41 Download
2 Crossref

Telomerase Activity in Gastric Adenocarcinomas: Frozen Tissues Versus Methacarn-fixed Paraffin-embedded Tissues: Jinyoung Yoo, Seok Jin Kang, Chang Suk Kang; Cancer Res Treat. 2003;35(6):478-482. Published online December 31, 2003; DOI: https://doi.org/10.4143/crt.2003.35.6.478

Abstract PDF: PURPOSE
Telomerase is an RNA-dependent DNA polymerase that synthesizes TTAGGG telomeric DNA onto chromosome ends to compensate for sequence loss during DNA replication. It has been detected in 85~90% of all primary human cancers, implicating that its apparent reactivation in tumors may play a role in the tumorigenic process. The purpose of this study was to evaluate telomerase activity in stomach cancer, and to determine whether methacarn-fixed paraffin-embedded tissues can replace frozen tissue sections for the telomerase (TRAP) assay. MATERIALS AND METHODS: Frozen and corresponding methacarn-fixed paraffin-embedded tissue samples were obtained from 51 patients with gastric adenocarcinoma and analyzed for telomerase activity by using a TRAPeze ELISA kit. RESULTS: Telomerase activity was detected in 37 (73%) frozen samples, and in 13 (25%) methacarn-fixed paraffin blocks. Telomerase activity was well correlated with depth of invasion (p=.037) and tumor differentiation (p=.022). CONCLUSION: These data suggest that reactivated telomerase may play a significant role in the tumorigenesis of gastric cancer and may reflect the malignant potential of the tumor. It is noteworthy that methacarn- fixed tissue cannot as yet substitute for the frozen tissue in the TRAP assay.

3,660 View
18 Download

Case Reports

M llerian-Type Gland Inclusions in Pelvic Lymph Nodes Mimicking Metastasis: A Case Report and Review of the Literature: Jinyoung Yoo, Hyun Joo Choi, Seok Jin Kang; Cancer Res Treat. 2003;35(2):165-167. Published online April 30, 2003; DOI: https://doi.org/10.4143/crt.2003.35.2.165

Abstract PDF

Benign lymph node inclusions are rare, and can be mistaken for metastasis. We report, herein, a case of a 50-year-old woman who underwent a hysterectomy, with a lymphadenectomy, for an endometrial carcinoma. There was no lymph node metastasis; however, the left external and common iliac lymph nodes demonstrated a few glands, consistent with M llerian-type inclusions (endosalpingiosis). Awareness of these lesions is important to avoid either unnecessary therapy or any delay in treatment. Furthermore, pelvic and aortic lymphadenectomies may be warranted, as neoplastic transformation of preexisting metaplastic tubal-type epithelium is strongly suggested. This paper presents a case of intranodal endosalpingiosis mimicking metastasis.

Citations

Citations to this article as recorded by

Intraoperative Appearance of Endosalpingiosis: A Single-Center Experience of Laparoscopic Findings and Systematic Review of Literature
Laurin Burla, Dimitrios Rafail Kalaitzopoulos, Anna Mrozek, Markus Eberhard, Nicolas Samartzis
Journal of Clinical Medicine.2022; 11(23): 7006. CrossRef
Endosalpingiose – ein irrelevanter laparoskopischer Zufallsbefund?
Laurin Burla, Dimitrios Rafail Kalaitzopoulos, Markus Eberhard, Nicolas Samartzis
Praxis.2021; 110(14): 804. CrossRef
Primary lesions that may imitate metastatic tumors histologically: A selective review
Mark R. Wick
Seminars in Diagnostic Pathology.2018; 35(2): 123. CrossRef

3,621 View
28 Download
3 Crossref

Invasive Ductal Carcinoma of the Male Breast: A Case Report and Review of the Literature: Jinyoung Yoo, Hyun Joo Choi, Hee Jeong Lee, Seok Jin Kang, Byung Kee Kim, Sang In Shim, Chang Suk Kang; Cancer Res Treat. 2002;34(3):239-242. Published online June 30, 2002; DOI: https://doi.org/10.4143/crt.2002.34.3.239

Abstract PDF: Breast carcinomas are an uncommon neoplastic condition in men, accounting for only 1% of all breast cancers, and less than 1% of all malignancies in men. A 70-year-old man who presented a right breast mass was found to have infiltrating ductal carcinoma. We herein report the case with a review of the literature.

4,971 View
89 Download

Original Article

Telomerase Activity and Expression of hTR and TERT in Human Soft Tissue Sarcomas: Jinyoung Yoo, Seok Jin Kang, Byung Kee Kim; Cancer Res Treat. 2002;34(1):46-51. Published online February 28, 2002; DOI: https://doi.org/10.4143/crt.2002.34.1.46

Abstract PDF

PURPOSE
Sarcomas have rarely been analyzed for telomerase, which is an RNA-dependent DNA polymerase to maintain telomeres and prevent telomere shortening. This study was undertaken to determine telomerase activity and the expression of the telomerase subunits human telomerase RNA (hTR) and telomerase reverse transcriptase (TERT) in soft tissue sarcomas.
MATERIALS AND METHODS
Twenty three sarcomas were analyzed for the telomerase activity by a radioactive PCR-based TRAP assay. All of the samples were further investigated for the expression of hTR by in situ hybridization and for TERT and p53 by immunohistochemistry.
RESULTS
Telomerase activity was detected in four (17%) samples. Expression of hTR was demonstrated in 11 (48%) cases, whereas TERT was expressed in 20 (87%).Of the four telomerase-positive tumors, three were positive for both hTR and TERT, and one was positive only for TERT. p53 overexpression was observed in nine (39%) tumors. The frequency of p53 expression increased as the tumor grade advanced (p= .064).
CONCLUSION
These data indicate that the reactivation of telomerase is an uncommon event in human soft tissue sarcomas. The high frequency of the expression of hTR and TERT in these tumors suggests that telomerase activity may be regulated at the transcriptional level and an additional event leading to telomerase activation exist.

Citations

Citations to this article as recorded by

Concomitant underexpression of TGFBR2 and overexpression of hTERT are associated with poor prognosis in cervical cancer
Hui Yang, Hongyan Zhang, Yahua Zhong, Qiaoli Wang, Lei Yang, Hong Kang, Xiaojia Gao, Haijun Yu, Conghua Xie, Fuxiang Zhou, Yunfeng Zhou
Scientific Reports.2017;[Epub] CrossRef

4,291 View
28 Download
1 Crossref

First
Prev
Page of 1
Next
Last

Search